This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Day, C. Articles by Bailey, C. J Search for Related Content Social Bookmarking                         What's this?

Review: Pharmacological approaches to reduce adiposity

Diabetes Research Group, School of Life and Health Sciences, Aston University, Aston Triangle, Birmingham, B4 7ET, UK, cday{at}mededuk.com

Clifford J Bailey

A catalogue of antiobesity agents came and went during the last century. The current weight loss agents orlistat and sibutramine are now to be joined by rimonabant, a cannabinoid-1 (CB1) receptor antagonist that acts centrally to decrease appetite and peripherally to reduce lipogenesis in adipose tissue. Use of rimonabant is based on evidence that the endogenous cannabinoid system is overactive in obesity, mainly due to increased expression of CB1 receptors. Weight loss attributed to rimonabant (about 5 kg over one year) was associated with improved insulin sensitivity, reduced triglyceride and increased high density lipoprotein cholesterol. Like other antiobesity agents rimonabant should be used as an adjunct to lifestyle advice. Although there are several potential antiobesity agents in development these are mostly at an early stage of clinical evaluation.

Key Words: obesity • rimonabant • orlistat • sibutramine.

References

• WHO fact sheet: Obesity and overweight 2003. www.who.int/topics/obesity/en/ (accessed January 2005).
• UK national audit office. Tackling obesity in England 2003. www.nao.gove.uk/publications/nao_reports/00-01/0001220 (accessed May 2006)
• Haslam DW, James WPT. Obesity. Lancet 2005;366:1197-209.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Sjostrom L., Rissanen A., Anderson T. et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998;352:167-73.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• James WPT, Astrup A., Finer N. et al. Effect of sibutramine on weight maintenance and weight loss: a randomised trial. Lancet 2000;356: 2119-25.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Li Z., Maglione M., Tu W. et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005;142:532-46.[Abstract/Free Full Text]
• Ioannides-Demos LL, Proietto J., McNeil JJ Pharmacotherapy for obesity. Drugs 2005;65:1391-418.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• World Health Organization. Obesity: preventing and managing the global epidemic. Geneva. Switzerland: Report of a WHO consultation, 2000. Technical Report Series 894.
• Bray GA Pharmacological treatment of obesity. In Handbook of Obesity, Bray GA, Buchard C, James WPT (eds). New York: Marcel Dekker, 1998, pp 953-75.
• Goldstein DJ, Rampey AH, Enas GG et al. Fluoxetine: a randomized clinical trial in the treatment of obesity. Int J Obesity 1994;18:129-35.[Web of Science][Medline] [Order article via Infotrieve]
• Wilding J., van Gaal L., Rissanen A. et al. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Int J Obesity Relat Metab Disord 2004; 28:1399-410.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Gadde KM, Franciscy DM, Wagner HR, Krishman KRR. Zonisamide for weight loss in obese adults. A randomized controlled trial. JAMA 2003; 289:1820-5.[Abstract/Free Full Text]
• Anderson JW, Greenway FL, Fujioka K. et al. Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obesity Res 2002;10:633-41.[Web of Science][Medline] [Order article via Infotrieve]
• Heymsfield SB, Greenberg AS, Fujioka K. et al. Recombinant leptin for weight loss in obese and lean adults. A randomized controlled, doseescalation trial. JAMA 1999;282:1568-75.
• Ettinger MP, Littlejohn TW, Schwartz SL et al. Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults. A randomized, dose-ranging study. JAMA 2003;289:1826-32.
• Cota D., Marsicano G., Tschop M. et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003;112:423-31.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Di Marzo V., Bifulco M., De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 2004;3:771-84.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Pertwee RG Pharmacological actions of cannabinoids. Handb Exp Pharmacol 2005;168:1-51.[CrossRef][Medline] [Order article via Infotrieve]
• Van Gaal LF, Rissanen AM, Scheen AJ et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1 year experience from the RIO-Europe study. Lancet 2005;365:1389-97.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Despres JP, Golay A., Sjostrom L. et al. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005;353:2121-34.[Abstract/Free Full Text]
• Pi-Sunyer X., Aronne LJ, Heshmati HM Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006;295:761-75.[Abstract/Free Full Text]
• Holt R. New drugs for obesity. Diabetes Obesity Metabolism 2004,6:464.
• Krentz AJ, Bailey CJ Oral antidiabetic agents. Current role in type 2 diabetes mellitus. Drugs 2005;65:385-411.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Day C. Amylin analogue as an antidiabetic agent. Br J Diabetes Vasc Dis 2005;5:151-4.[Abstract/Free Full Text]
• Schnabel CA The incretin mimetic, exenatide: a novel treatment option for type 2 diabetes. Br J Diabetes Vasc Dis 2005;5:227-35.[Abstract/Free Full Text]
• Kendall DM, Riddle MC, Rosenstock J. et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083-91.[Abstract/Free Full Text]
• Batterham RL, Cohen MA, Ellis SM et al. Inhibition of food intake in obese subjects by peptide YY 3-36. New Engl J Med 2003;349:941-8.[Abstract/Free Full Text]
• Cummings DE, Weigle DS, Frayo RS Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002;346:1623-30.[Abstract/Free Full Text]
• Walker BR 11β-hydroxysteroid dehydrogenase type 1 in obesity. Obesity Res 2004;12:1-3.[Web of Science][Medline] [Order article via Infotrieve]
• Evans RM, Barish GD, Wang YX PPARs and the complex journey to obesity. Nature Med 2004;10:1-7.[CrossRef][Web of Science]
• Hoodia gordonii ohttp://www.phytopharm.co.uk/hoodia_faq.html (accessed May 2006).
• MacLean DB, Luo LG Increased ATP content/production in the hypothalamus may be a signal for energy-sensing of satiety: studies of the anorectic mechanism of a plant steroidal glycoside. Brain Res 2004;1020:1-11.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

The British Journal of Diabetes & Vascular Disease, Vol. 6, No. 3, 121-125 (2006)
DOI: 10.1177/14746514060060030401


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				H. Purcell and C. Day Achieving acceptable adiposity The British Journal of Diabetes & Vascular Disease, July 1, 2008; 8(4): 159 - 161. [PDF]

				Early and intensive treatment: glycaemic control in type 2 diabetes Diabetes and Vascular Disease Research, December 1, 2006; 3(3): 145 - 146. [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Day, C. Articles by Bailey, C. J Search for Related Content Social Bookmarking                         What's this?